Astellas Pharma Pension Fund

Shigeo Takedo serves as Executive Director overseeing pension fund operations, including investment decisions. The fund operates with an internal team, though the full organizational chart is not publicly disclosed. As a corporate pension fund, the investment committee structure and any external advisory relationships remain private, consistent with most Japanese corporate plans.

As a Japanese corporate pension, the fund primarily accesses private-market managers through established placement-agent relationships, on-the-ground fund-manager meetings in Tokyo, and domestic gatekeeper platforms. Japanese institutional LPs commonly rely on trust banks and securities-firm intermediary services for fund introduction and due-diligence support in venture and private equity.

Based on available commitment data, the fund participates through fund commitments and fund-of-funds structures. Direct co-investment activity alongside GPs has not been publicly documented, though co-investment programs are increasingly common among Japanese corporate pension funds pursuing private equity exposure.

Commitment records indicate the fund targets the full private-equity lifecycle: early-stage venture (including seed), expansion and late-stage venture, growth equity, buyout, and mezzanine. The fund maintains relationships with managers across the liquidity spectrum, not concentrating exclusively on any single stage.

Astellas Pharma Inc. operates a separate corporate venture and business-development unit that makes strategic pharma investments. The pension fund and corporate venture arm operate under distinct mandates: the pension fund pursues financial returns for retirement beneficiaries, while Astellas Venture Management targets strategic innovation aligned to the parent company's therapeutic pipelines. Japanese pension governance rules require this separation.

The fund does not publicly report its total assets under management. Japanese corporate pension funds are not uniformly required to publish standalone AUM figures, especially if they are structured as a non-public trust. Astellas Pharma Inc. reports aggregate retirement benefit obligations in its annual securities filings, but the specific carve-out for the Japanese pension plan is not separately disclosed in English-language documents.

The fund's commitments concentrate on Japan-based managers alongside allocations to US and pan-Asia fund managers. The domestic Japan bias is typical of Japanese corporate pension funds, which balance local return requirements with the deeper private-markets opportunity set in North America and broader Asia-Pacific.